Supernus Pharmaceuticals, Inc. revenue
Supernus Pharmaceuticals, Inc.'s revenue was $719m in fiscal 2025, up 8.6% on the year before. Since fiscal 2010 ($106,000) it has grown at a compound 80.1% a year. Over the last twelve months it was $865m.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 1 | 12 | 93 | 147 | 215 | 302 | 409 | 393 | 520 | 580 | 667 | 608 | 662 | 719 | 865 |
| Growth on the year before | — | +657.5% | +84.3% | +712.1% | +671.1% | +59.1% | +45.8% | +40.6% | +35.3% | −3.9% | +32.5% | +11.4% | +15.1% | −8.9% | +8.9% | +8.6% | — |
| Gross profit | — | — | — | — | — | — | 203 | 287 | 394 | 376 | 468 | — | 580 | 524 | 584 | 644 | 758 |
| Gross margin | — | — | — | — | — | — | 94.4% | 95.0% | 96.2% | 95.8% | 89.9% | — | 86.9% | 86.2% | 88.2% | 89.6% | 87.6% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $627M | 87.2% | ▼ 1.8% |
| Qelbree (part of Products) | $305M | 48.6% | ▲ 26.3% |
| GOCOVRI (part of Products) | $147M | 23.4% | ▲ 12.2% |
| Collaboration Revenue (part of Products) | $53M | 8.5% | — |
| Trokendi Xr (part of Products) | $42.4M | 6.8% | ▼ 32.9% |
| Oxtellar XR (part of Products) | $40.7M | 6.5% | ▼ 59.1% |
| Royalty License and Other Revenue (part of Products) | $39.4M | 6.3% | ▲ 63.4% |
| APOKYN | $47.8M | 6.6% | ▼ 35.4% |
| Manufactured Product Other | $26.9M | 3.7% | ▼ 7.2% |
| ONAPGO | $17.3M | 2.4% | — |
From Supernus Pharmaceuticals, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $865m | 26.9% | 12.3% |
| Axsome Therapeutics, Inc. | $865m | 54.2% | 57.0% |
| Corcept Therapeutics Inc | $831m | 16.0% | 24.7% |
| Harmony Biosciences Holdings, Inc. | $960m | 24.3% | 24.4% |
| ANI Pharmaceuticals Inc | $978m | 30.9% | 34.6% |
| Pacira Biosciences, Inc. | $746m | 5.7% | 3.7% |
Compare with peers
- Axsome Therapeutics, Inc. revenue
- Corcept Therapeutics Inc revenue
- Harmony Biosciences Holdings, Inc. revenue
- ANI Pharmaceuticals Inc revenue
- Pacira Biosciences, Inc. revenue
Head to head: AXSM vs SUPNCORT vs SUPNHRMY vs SUPN
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies